Targeting of Cisplatin-Resistant Melanoma Using a Multivalent Ligand Presenting an Elastin-like Polypeptide

Area of Science:

• Biomaterials Science
• Nanotechnology
• Oncology

Background:

• Acquired drug resistance is a primary cause of melanoma treatment failure, particularly resistance to cisplatin.
• Targeted drug delivery systems are crucial for overcoming drug resistance, enhancing therapeutic efficacy, and minimizing side effects in cancer treatment.

Purpose of the Study:

• To engineer a macromolecular carrier that specifically targets cisplatin-resistant (Cis-R) melanoma.
• To evaluate the targeting specificity and efficacy of the engineered carrier in vitro and in vivo.

Main Methods:

• Genetic engineering of a macromolecular carrier using recursive directional ligation.
• The carrier, M16E108, comprises an elastin-like polypeptide (ELP) with multiple cisplatin-resistant melanoma-targeting ligands (M-peptide).
• Evaluation of M16E108 accumulation in Cis-R B16F10 and parental B16F10 melanoma cells, and in tumor tissues of bearing mice.

Main Results:

• The M16E108 carrier demonstrated specific accumulation in cisplatin-resistant B16F10 melanoma cells compared to parental cells.
• In vivo studies showed efficient homing and prolonged retention of M16E108 in tumor tissues of Cis-R melanoma-bearing mice.
• The carrier's thermal phase transition was optimized at 39 °C for potential therapeutic applications.

Conclusions:

• The engineered M16E108 carrier exhibits specific targeting capabilities for cisplatin-resistant melanoma.
• M16E108 shows significant potential as a novel therapeutic agent for overcoming cisplatin resistance in melanoma.
• This targeted delivery system offers a promising strategy to improve melanoma treatment outcomes.